| Name | Title | Contact Details |
|---|---|---|
Karthik Eticala |
Vice President, Manufacturing and Supply Chain | Profile |
Endobiologics is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Akero Therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.
EpicentRx is a patient-driven immuno-oncology company with minimally toxic therapies that work across diverse patient populations and tumor types for the best possible quality of life during treatment.
Impact Biomedicines, Inc. (Impact) is pioneering the development of life-changing treatments for patients with myeloproliferative neoplasms and other cancers. Led by a highly skilled and devoted team, Impact is advancing a late-stage pipeline centered around fedratinib, a potent and highly selective oral small molecule JAK2 kinase inhibitor, which is being developed initially for the treatment of myelofibrosis (MF) and polycythemia vera (PV). Impact was formed in 2016 after acquisition of Sanofi’s full rights for the global development and commercialization of fedratinib. The Impact team intends to pursue multiple clinical indications for fedratinib to maximize its potential as a best-in-class therapy for JAK2-dependent diseases.
Epirium Bio is a clinical-stage biopharmaceutical company developing therapeutics that promote mitochondrial biogenesis and function through a novel mechanism of action discovered by the company.